Kahn Brothers Group Inc. DE Sells 39,468 Shares of Pfizer Inc. (NYSE:PFE)

Kahn Brothers Group Inc. DE lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 770,316 shares of the biopharmaceutical company’s stock after selling 39,468 shares during the period. Pfizer comprises 4.6% of Kahn Brothers Group Inc. DE’s investment portfolio, making the stock its 10th largest holding. Kahn Brothers Group Inc. DE’s holdings in Pfizer were worth $25,143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth about $2,326,225,000. Capital World Investors increased its holdings in shares of Pfizer by 13.4% in the 4th quarter. Capital World Investors now owns 188,715,390 shares of the biopharmaceutical company’s stock valued at $7,393,867,000 after purchasing an additional 22,232,056 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Pfizer by 205.9% in the 4th quarter. Renaissance Technologies LLC now owns 13,102,541 shares of the biopharmaceutical company’s stock valued at $513,358,000 after purchasing an additional 8,819,241 shares during the period. Swiss National Bank increased its holdings in shares of Pfizer by 20.9% in the 1st quarter. Swiss National Bank now owns 23,038,291 shares of the biopharmaceutical company’s stock valued at $751,970,000 after purchasing an additional 3,985,000 shares during the period. Finally, Marshall Wace North America L.P. increased its holdings in shares of Pfizer by 77.2% in the 4th quarter. Marshall Wace North America L.P. now owns 8,091,140 shares of the biopharmaceutical company’s stock valued at $317,010,000 after purchasing an additional 3,525,078 shares during the period. Hedge funds and other institutional investors own 69.91% of the company’s stock.

In other Pfizer news, major shareholder Pfizer Inc purchased 312,500 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 2,181 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total value of $83,641.35. Following the transaction, the senior vice president now owns 9,647 shares of the company’s stock, valued at $369,962.45. The disclosure for this sale can be found here. 0.08% of the stock is owned by corporate insiders.

A number of brokerages have recently weighed in on PFE. Morgan Stanley dropped their target price on Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a report on Thursday, April 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $37.00 target price on shares of Pfizer in a report on Tuesday, January 28th. Royal Bank of Canada reiterated a “buy” rating and issued a $44.00 target price on shares of Pfizer in a report on Monday, April 27th. Barclays upped their target price on Pfizer from $36.00 to $37.00 and gave the company an “equal weight” rating in a report on Wednesday, April 29th. Finally, Standpoint Research upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $41.28.

Pfizer stock traded up $0.24 during trading hours on Friday, reaching $37.50. 14,885,114 shares of the company were exchanged, compared to its average volume of 22,354,300. The firm has a market cap of $206.97 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 2.72 and a beta of 0.71. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average of $36.51 and a 200 day moving average of $36.84. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $44.56.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. The firm had revenue of $12.03 billion during the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The company’s revenue was down 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.85 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.81 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 8th will be given a dividend of $0.38 per share. The ex-dividend date is Thursday, May 7th. This represents a $1.52 dividend on an annualized basis and a yield of 4.05%. Pfizer’s payout ratio is currently 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: When can a hold rating present a buying opportunity?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.